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Background: Growing awareness of the complexity of carcinogenesis has made multimodal therapies for cancer
increasingly compelling and relevant. In recent years, immunotherapy has gained acceptance as an active
therapeutic approach to cancer treatment, even though cancer is widely considered an immunosuppressive
disease. Combining immunotherapy with targeted agents that have immunomodulatory capabilities could
significantly improve its efficacy.
Methods: We evaluated the ability of cabozantinib, a receptor tyrosine kinase inhibitor, to modulate the immune
system in vivo as well as alter the phenotype of tumor cells in vitro in order to determine if this inhibitor could act
synergistically with a cancer vaccine.
Results: Our studies indicated that cabozantinib altered the phenotype of MC38-CEA murine tumor cells, rendering
them more sensitive to immune-mediated killing. Cabozantinib also altered the frequency of immune sub-populations
in the periphery as well as in the tumor microenvironment, which generated a more permissive immune environment.
When cabozantinib was combined with a poxviral-based cancer vaccine targeting a self-antigen, the combination
significantly reduced the function of regulatory T cells and increased cytokine production from effector T cells in
response to the antigen. These alterations to the immune landscape, along with direct modification of tumor cells, led
to markedly improved antitumor efficacy.
Conclusions: These studies support the clinical combination of cabozantinib with immunotherapy for the treatment
of cancer.
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Cabozantinib, a small molecule inhibitor of multiple re-
ceptor tyrosine kinases (RTKs) [1], was approved in
2012 by the U.S. Food and Drug Administration (FDA)
for the treatment of patients with progressive, metastatic
medullary thyroid cancer [2]. Much of cabozantinib’s ef-
ficacy in this setting may derive from its inhibition of
the RET RTK [3,4]. Cabozantinib also inhibits MET and
VEGFR2, two RTKs believed to play major roles in the
growth and dissemination of cancer cells. MET, the only
known receptor for hepatocyte growth factor, functions
to influence cell survival, proliferation, migration, and
invasion. MET signaling can also affect tumor angiogen-
esis by stimulating VEGF and VEGFR expression, down-
regulating thrombospondin-1, and inducing tubulogenesis
[5]. Mutation, amplification, and/or overexpression of the
gene encoding MET has been observed in many tumor
types, and in many cases has been associated with in-
creased cancer aggressiveness, poor prognosis, and ac-
quired resistance to standard therapies [6-11]. The VEGF
pathway of tumor angiogenesis has been targeted exten-
sively with antibody and small molecule inhibitor therap-
ies [12-14]. However, in many cases, tumors overcome the
initial inhibition of angiogenesis mediated by these therapies,
in some cases due to an upregulation of MET signaling
[15]. The dual inhibition of MET and VEGFR2 by cabo-
zantinib may account for its activity in additional tumor
types such as metastatic castration-resistant prostate can-
cer, renal cell carcinoma, and hepatocellular carcinoma, in
which it is currently in phase III clinical trials [16-18].
Currently, the FDA has approved a limited number of
immunotherapeutic agents for the treatment of cancer.
These include sipuleucel-T, an autologous dendritic-cell
vaccine for prostate cancer, ipilimumab, a monoclonal
antibody that blocks the CTLA-4 inhibitory signal, and
most recently pembrolizumab, a PD-1 inhibitor which
also joins IL-2 and interferon-alpha for the treatment of
melanoma [19-23]. However, many more immunother-
apies, including poxviral-based cancer vaccines, are in
late-stage clinical trials and are exhibiting substantial
anti-tumor activity in multiple clinical settings [24-26].
Immunotherapeutic drugs have had positive clinical
results as single agents. However, given the immunosup-
pressive nature of cancer, there is considerable room for
improvement [27-29]. Combining immunotherapy with
other targeted agents that have immunomodulatory cap-
abilities in addition to antitumor properties has the po-
tential to enhance its clinical benefit. Our studies have
focused on two mechanisms for altering antitumor im-
mune responses: immunogenic modulation and immune
subset conditioning. Immunogenic modulation has been
defined as the alteration of tumor cell phenotype such
that the tumor cell becomes more sensitive to T cell-
mediated lysis, most commonly through a modificationof cell surface molecule expression. Standard therapies such
as radiation, chemotherapy, and, most recently, androgen-
deprivation therapy, have been shown to induce immuno-
genic modulation [30-33]. Immune subset conditioning
involves altering the frequency and/or activity of immune
cell subsets in the periphery and the tumor microenviron-
ment, enabling more productive immune interactions lead-
ing to improved antitumor effects. Small molecule inhibitors
have been shown to induce immune subset conditioning
[34,35]. To date, however, no cancer therapy has been shown
to mediate both immunogenic modulation and immune sub-
set conditioning.
This study sought to investigate the ability of cabozanti-
nib to improve the sensitivity of tumor cells to immune
mediated lysis through immunogenic modulation and alter
the immune landscape, both peripherally and in the tumor
microenvironment (immune subset conditioning). We hy-
pothesized that such effects could enable more productive
immune interactions, potentially leading to synergistic an-
titumor effects when combining cabozantinib with a
poxviral-based cancer vaccine. Here, we show that cabo-
zantinib can (a) modulate the phenotype of tumor cells,
making them more susceptible to T cell-mediated lysis, (b)
modify the composition of the peripheral and tumor
microenvironment immune compartments, (c) alter im-
mune cell function, and (d) induce sustained CD4+ and
CD8+ T cell-dependent tumor regression when combined
with a poxviral-based cancer vaccine. Taken together,
these findings suggest that cabozantinib is capable of
both immunogenic modulation and immune subset
conditioning, supporting its clinical combination with
cancer immunotherapy.
Results
Cabozantinib reduced the proliferation of MC38-CEA
tumor cells
We used the MC38-CEA murine colon carcinoma cell
line which expresses both VEGFR2 and MET (Figure 1A,
inset), in addition to the human carcinoembryonic anti-
gen (CEA), to examine the in vitro immunomodulatory
effects and in vivo antitumor effects of cabozantinib.
First, we determined the effect of cabozantinib on the
proliferation of MC38-CEA cells. MC38-CEA cells were
exposed to 2.5 μg/mL cabozantinib for 24, 72, or 120 h
to model the steady-state plasma concentration achiev-
able in humans [3]. After the designated period of treat-
ment, cells were harvested and counted, and their
viability was measured. Cabozantinib significantly re-
duced the proliferation of MC38-CEA cells after 72 and
120 h (Figure 1A). However, despite this reduction, the
MC38-CEA cells continued to proliferate and their via-
bility remained >75% at all time points, regardless of
treatment. We therefore used this dose of cabozantinib
for all subsequent in vitro studies.
Figure 1 Cabozantinib inhibits the growth, alters the phenotype and increases the sensitivity of MC38-CEA cells to T cell-mediated
killing. (A) MC38-CEA cells were treated with 2.5 μg/mL cabozantinib or vehicle for 1, 3, and 5 days then assayed for growth and viability. Inset
panel: MET and VEGFR2 expression of MC38-CEA cells. (B) MC38-CEA cells were exposed to 2.5 μg/mL cabozantinib or vehicle for 24 h, then
analyzed by flow cytometry for surface expression of CEA, MHC-I (H-2Kb, H-2Db), ICAM-1, Fas, and calreticulin. Percent positivity and mean
fluorescence intensity, in parentheses, are shown. Values in bold denote an increase of >40% relative to vehicle-treated cells. (C, D) MC38-CEA
cells treated with cabozantinib (black bars) or vehicle (open bars) or left untreated (gray bars) for 24 h were labeled with 111In, then coincubated
with CTLs specific for CEA (C) or gp70 (D) for 18 h at a ratio of 30:1. Bars indicate mean ± SEM. from quadruplicate measurements. Statistical
analyses were done by Student’s t test. * = P <0.01. Data are representative of 3 independent experiments.
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markers associated with immune recognition
It has been previously shown that radiation and chemo-
therapy can alter the phenotype of tumor cells, render-
ing them more sensitive to T cell-mediated killing
[31,32,36]. To determine if cabozantinib could modify
the expression of cell-surface markers that influence im-
mune recognition, we treated MC38-CEA cells with
cabozantinib for 24 h, then stained and analyzed them
by flow cytometry. Cabozantinib significantly upregu-
lated the expression of MHC-I molecules on both the
population level (H-2Db) and a per-cell basis (H-2Kb),
increasing the potential for antigen presentation and T
cell recognition of the tumor cells (Figure 1B). Cabozanti-
nib treatment also increased the percentage of MC38-CEA
cells expressing ICAM-1, Fas, and calreticulin, cell-surfacemarkers that also aid in T cell recognition, adhesion, and
stimulation (Figure 1B). Prior studies have suggested that
altering the expression of any one of these markers was
capable of making tumor cells more amenable to T cell-
mediated killing [31,32,36-38].
Cabozantinib increased the sensitivity of MC38-CEA cells
to T cell-mediated killing
To determine if cabozantinib treatment could increase
the sensitivity of MC38-CEA cells to T cell-mediated
lysis, we treated cells for 24 h, then used them as targets
in CTL killing assays. Cabozantinib treatment signifi-
cantly increased the sensitivity of MC38-CEA cells to T
cell-mediated lysis by cytotoxic T lymphocytes (CTLs)
specific for CEA (P =0.0004) (Figure 1C) as well as the
endogenously expressed tumor antigen gp70 (P =0.0075)
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treatment made tumor cells more susceptible to killing
by other therapies or if their increased susceptibility was
specific to T cell-mediated killing. We treated MC38-
CEA cells with cabozantinib for 24 h, then exposed them
to 0 or 5 Gy external-beam radiation and replated them
in the absence of cabozantinib. Cells were counted and
assayed for viability 24, 48, and 72 h post-irradiation.
Administration of external-beam radiation further re-
duced the growth of cabozantinib-treated MC38-CEA
cells, but did not reduce their viability as the cells
remained >75% viable regardless of treatment (Additional
file 1). Taken together, these data suggested that cabozan-
tinib was capable of specifically altering tumor cells in
ways that made them more amenable to immune medi-
ated attack.
Cabozantinib treatment altered the composition of the
peripheral immune environment
To assess the impact of cabozantinib treatment on the per-
ipheral immune environment, CEA-Tg C57/BL6 mice were
fed a cabozantinib-compounded diet for up to 35 days.
After 10 days on this diet, mice achieved a cabozantinib
serum concentration of 2.77 ± 1.14 μg/mL, which was
similar to the steady-state serum concentration achieved at
the maximum tolerated dose in a phase I human clinical
trial (2.31 μg/mL; Figure 2A) [3]. At 35 days, cabozantinib
treatment did not affect the total number of splenocytes in
treated mice (Figure 2B), nor did it significantly increase
the percentage of CD4+ T cells in the spleen (P =0.1585)
(Figure 2C). Cabozantinib treatment did, however, increase
the percentage of CD8+ T cells (P =0.0198) (Figure 2D). In
addition, treatment with cabozantinib reduced the percent-
age of T regulatory cells (Tregs) (P =0.0152) (Figure 2E),
and myeloid-derived suppressor cells (MDSCs) (P <0.0001)
in the spleen (Figure 2F). As a result of these alterations,
CD4:Treg/MDSC ratios improved from 13.34 to 16.43 and
4.14 to 7.59, respectively even in the absence of a signifi-
cant change in the level of CD4+ T cells. CD8:Treg/MDSC
ratios improved from 8.24 to 11.91 and 2.54 to 5.50, re-
spectively, due to the significant alteration of CD8+ T cells,
Tregs, and MDSCs. These changes in immune-cell com-
position were evident as early as 10 days after initiating
cabozantinib treatment. In addition, after 10 days of cabo-
zantinib treatment we observed a transient increase in the
percentage of CD4+ T cells (19.90% ±0.76 vs. 27.44% ±0.65;
P <0.0001); however, this increase waned by day 35.
Cabozantinib therapy synergized with a therapeutic
cancer vaccine to improve T cell proliferation and
function
After determining that cabozantinib could alter the
peripheral immune landscape, we next combined it with
a poxviral-based cancer vaccine to determine if thecombination could alter the function of immune cells as
well. Cabozantinib and MVA/rF-CEA/TRICOM were
administered to CEA-Tg C57/BL6 mice as indicated in
Figure 3A. After 35 days, splenocytes were harvested
and Tregs were purified to assay their ability to regulate
the proliferation of naïve CD4+ T cells. Compared
to Tregs from control mice, Tregs from mice treated
with cabozantinib alone demonstrated a significantly re-
duced ability to regulate the proliferation of CD4+ T cells
(P =0.0183) (Figure 3B). Surprisingly, the regulatory cap-
acity of Tregs from mice treated with MVA/rF-CEA/TRI-
COM alone was also significantly reduced (P =0.0003)
(Figure 3B). However, the combination of cabozantinib
and MVA/rF-CEA/TRICOM completely abrogated Treg
function, as CD4+ T-cell proliferation in the presence of
Tregs from these mice was not significantly different from
that in the absence of Tregs (P =0.0775) (Figure 3B). Sple-
nocytes from these mice were also analyzed for CEA-
specific cytokine production. Splenocytes from mice
treated with the combination of cabozantinib and MVA/
rF-CEA/TRICOM produced significantly more interferon
(IFN)-γ (Figure 3C; P =0.0188) and tumor necrosis factor
(TNF)-α (Figure 3D; P =0.0015) than splenocytes from
control mice. In addition, splenocytes from mice treated
with the combination produced significantly more IFN-γ
than splenocytes from mice receiving either cabozantinib
alone (P =0.0463) or MVA/rF-CEA/TRICOM alone (P =
0.0020). Splenocytes from combination-treated mice also
produced significantly more TNF-α than splenocytes from
mice receiving MVA/rF-CEA/TRICOM alone (P =0.0022).
Cabozantinib treatment reduced tumor vascularity and
altered immune-cell infiltration when combined with a
cancer vaccine
It has been reported that cabozantinib reduces tumor
vascularity, primarily through the inhibition of VEGF re-
ceptors [1,39,40]. We sought to confirm this observation
in the MC38-CEA model and determine whether cabo-
zantinib could also affect infiltration of immune cells
into the tumor microenvironment when combined with
a cancer vaccine. We implanted CEA-Tg C57/BL6 mice
with MC38-CEA cells and treated them as indicated in
Figure 4A. Immunohistochemical analysis indicated that
cabozantinib treatment significantly reduced the vascular
density of MC38-CEA tumors compared to tumors from
control-treated mice (P =0.0166), and this reduction was
maintained when cabozantinib was combined with MVA/
rF-CEA/TRICOM (P =0.0249) (Figure 4B and C). In
addition, tumors from mice treated with the combination
of cabozantinib and MVA/rF-CEA/TRICOM showed
significantly increased infiltration of CD3+ lymphocytes
(P =0.0094) (Figure 4B and D, insert). Tumors from these
mice did not show a significant increase in CD4+ T-cell in-
filtration (Figure 4B and E), but did show a significant
Figure 2 Cabozantinib alters the immune-cell repertoire of C57BL/6 mice. (A) Serum concentration of cabozantinib in mice fed control diet
or diet containing cabozantinib for 10 days (n =5/group). Dashed line indicates the plasma concentration achieved at the maximum tolerated
dose in a phase 1 human clinical trial. (B) Number of viable cells/spleen in mice fed control diet or cabozantinib diet for 35 days. The frequency
of (C) CD4+ T cells (CD3+ CD4+), (D) CD8+ T cells (CD3+ CD8+), (E) Tregs (CD3+CD4+CD25+FoxP3+), and (F) MDSCs (CD11b+GR-1+) in spleens of
mice fed control diet or cabozantinib diet for 35 days was determined by flow cytometry. Error bars indicate mean ± SEM. Statistical analyses
were done by Student’s t test. * = P <0.05. Data are representative of 4 independent experiments.
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(P =0.0310) (Figure 4B and F). Flow cytometric analysis
revealed that the tumors from mice receiving cabozantinib
either alone or in combination with vaccine had a significantincrease in Treg infiltration (P =0.01-0.005, P =0.002-
0.001, respectively) (Figure 5A). However, cabozantinib
and, to a further extent, the combination of cabozantinib
and MVA/rF-CEA/TRICOM reduced the infiltration of
Figure 3 Combining cabozantinib with a cancer vaccine improves antigen-specific immune responses in CEA-Tg C57BL/6 mice. (A)
Schema of combination therapy study (n =9). (B) To evaluate Treg function, Tregs (CD3+CD4+CD25+FoxP3+) were isolated from spleens and
cocultured with CD4+ T cells from naïve mice, APCs (allogeneic splenocytes irradiated with 30 Gy), and soluble anti-CD3 for 72 h. Control wells
containing Tregs, APCs, and anti-CD3 without CD4+ T cells were used to determine the background level of Treg proliferation. Control wells
containing CD4+ T cells, APCs, and anti-CD3 without Tregs were used to determine the background level of CD4+ T-cell proliferation. Error bars
indicate mean ± SEM. Statistical analyses were done by Student’s t test. * = P <0.01 relative to CD4+ T-cell proliferation in the presence of Tregs
from untreated mice; n.s. indicates no significant difference between the proliferation of CD4+ T cells in the absence of Tregs or in the presence
of Tregs from mice treated with combination therapy. (C, D) To evaluate CD8+ T-cell responses, harvested splenocytes were incubated with
CEA peptide (1 μg/mL) for 7 days. Lymphocytes were then restimulated with fresh, irradiated, naïve splenocytes and 1 μg/mL of either CEA
or HIV-gag peptide for 24 h. Supernatants were collected and analyzed for murine IFN-γ (C) and TNF-α (D) using a cytometric bead array.
Nonspecific cytokine production in response to HIV-gag was subtracted from that induced by the CEA peptide. Error bars indicate mean ± SEM.
Statistical analyses were done by Student’s t test. * = P <0.05 relative to control and single-agent treatments. Data are representative of 2
independent experiments.
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(Figure 5B). Treatment with either cabozantinib or
MVA/rF-CEA/TRICOM alone reduced the percentage
of infiltrating tumor-associated macrophages (TAMs)
(P =0.01–0.005), but again, the combination further re-
duced TAM infiltration (Figure 5C). Taken together,
these data show that cabozantinib induces a more
immune-permissive environment, both in the peripheryand at the tumor site, and that this altered environment
may be exploited by combining cabozantinib with a
cancer vaccine.
Combination with a cancer vaccine further improved
cabozantinib’s antitumor activity
We evaluated the antitumor activity of cabozantinib in
the MC38-CEA tumor model with and without the
Figure 4 (See legend on next page.)
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Figure 4 Cabozantinib reduces tumor vascularity and improves T cell infiltration when combined with a cancer vaccine. (A) Schema of
combination therapy study (n =2/group). (B) Representative histological staining for indicated markers (top) on tumor sections from mice given
indicated treatments (left). Inset panels: isotype staining. (C–F) Quantification of (C) blood vessels/tumor section; (D) number of CD3+ T-cells/
tumor section; (E) number of CD4+ T-cells /tumor section; and (F) number of CD8+ T-cells /tumor section. Inset panels: number of indicated
cells/mm2 of tumor. Marker staining was identified and enumerated using Aperio ImageScope image analysis software. Error bars indicate
mean ± SEM. Statistical analyses were done by Student’s t test. * = P <0.05 relative to control.
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tinib treatment alone significantly reduced the growth rate
of MC38-CEA tumors compared to control (Figure 6B
and D). In addition, cabozantinib induced tumor regres-
sion in one mouse; this tumor reappeared, however, by
day 33. The combination of cabozantinib and MVA/
rF-CEA/TRICOM significantly reduced the growth rate of
MC38-CEA tumors compared to control and MVA/
rF-CEA/TRICOM alone. Additionally, 50% of the mice
treated with this combination had durable regression of
their tumors and remained tumor-free through day 35
(Figure 6E). Administration of cabozantinib prior to
MVA/rF-CEA/TRICOM did not further improve the anti-
tumor efficacy of the combination (data not shown). Also,
discontinuing cabozantinib after 10 days of treatment, or
administering a lower dose (3 mg/kg bw/day), reduced its
antitumor activity as a single agent and eliminated its
synergy with MVA/rF-CEA/TRICOM (data not shown).
Depleting either CD4+ or CD8+ T cells also abrogated the
antitumor activity observed when cabozantinib was com-
bined with MVA/rF-CEA/TRICOM suggesting a role for
both T cell subsets in the increased efficacy of the combin-
ation treatment (Figure 6F).
Discussion
Multiple studies have indicated that standard cancer treat-
ments such as chemotherapy and radiation therapy can
alter the phenotype of cancer cells, making them more
amenable to T cell-mediated lysis (immunogenic modula-
tion), or alter the immune landscape peripherally or in the
tumor microenvironment (immune subset conditioning),
indicating the potential for synergy with cancer immuno-
therapies [27]. We have previously demonstrated synergy
between sunitinib, a small molecule inhibitor, and the
MVA/rF-CEA/TRICOM cancer vaccine platform [34]. In
our studies, sunitinib reduced the number and function of
peripheral Tregs and MDSCs, induced lymphocyte prolif-
eration, and increased the percentage of circulating and
tumor-infiltrating CEA-specific CD8+ T cells. In tumor-
bearing mice, the combination of sunitinib and MVA/
rF-CEA/TRICOM reduced tumor growth and improved
overall survival [34]. Here we sought to further these find-
ings by examining cabozantinib, a novel RTK inhibitor, to
determine if it could also induce immune subset condi-
tioning due to an overlap of receptor inhibition with suni-
tinib. In addition, we hypothesized that, due to its slightlydifferent range of RTK inhibition, cabozantinib could po-
tentially induce immunogenic modulation, leading to even
greater synergy with cancer immunotherapy.
We found that treatment with cabozantinib alone in-
duced immune subset conditioning in the periphery.
Cabozantinib treatment significantly increased the fre-
quency of both CD4+ and CD8+ T cells in the spleen after
10 days of treatment with the increased frequency of
CD8+ Tcells being maintained through day 35 (Figure 2D).
MET signaling has been shown to suppress the inflamma-
tory response of macrophages as well as the activation and
function of dendritic cells [41-43]. Cabozantinib’s ability to
abrogate this suppression may influence antigen presenta-
tion by professional APCs, and therefore T-cell activation,
proliferation, and trafficking. Cabozantinib not only in-
creased the frequency of effector cells, but also signifi-
cantly reduced the frequency of negative immune
regulatory cells (Tregs and MDSCs) (Figure 2E and F). A
recent study has reported a similar reduction in circulating
Tregs in metastatic urothelial carcinoma patients treated
with cabozantinib, supporting the clinical relevance of
this finding [44]. It has been suggested that altering the
ratio between effector and regulatory cells could create
an immunostimulatory environment capable of break-
ing tolerance, thus allowing for the develpment of an
antitumor immune response against a self-antigen
[45-47]. When combined with MVA/rF-CEA/TRICOM,
a cancer vaccine directed toward a self-antigen, cabo-
zantinib increased the infiltration of lymphocytes, spe-
cifically CD8+ T cells, into the tumor microenvironment
(Figure 4D and F). Cabozantinib likely facilitated this in-
creased T cell infiltration through the direct reduction/
normalization of the tumor vasculature (Figure 4C) as
has been described by Huang, et al. [48]. In contrast,
cabozantinib reduced the infiltration of negative im-
mune regulatory cells, MDSCs and TAMs. This effect was
magnified when cabozantinib was combined with MVA/
rF-CEA/TRICOM, again generating a more permissive
immune environment (Figure 5B and C).
Cabozantinib alone had a significant impact on the
growth of MC38-CEA tumors in vivo (Figure 6D). This
effect could be primarily attributed to cabozantinib’s
significant impact on tumor vasculature (Figure 4C).
Cabozantinib alone, however, did not induce durable
tumor regression, without regrowth prior to day 35 of
treatment. Complete tumor regression, without regrowth,
Figure 5 Cabozantinib alters the tumor infiltration of negative
regulatory cell subsets. A portion of the tumors depicted in Figure 4
were homogenized into a single-cell suspension and analyzed by flow
cytometry for the presence of (A) Tregs (CD3+CD4+CD25+FoxP3+),
(B) MDSCs (CD11b+Gr-1+), and (C) TAMs (CD11b+Gr-1−). Statistical
analyses were done by Kolmogorov-Smirnov test. * = P <0.01
upregulation relative to control. ** = P <0.01 downregulation
relative to control.
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MVA/rF-CEA/TRICOM (Figure 6E) and required the
presence of both CD4+ and CD8+ T cells (Figure 6F). This
observation has been previously noted with this vaccine
platform and is likely due to a need for CD4+ cytokine
support by antigen specific CD8+ T cells [49]. Cabozanti-
nib also demonstrated increased efficacy when adminis-
tered prior to vaccine (data not shown). It is possible that
the reduced vascular density and increased lymphocytic
infiltration of the tumor, induced by cabozantinib treat-
ment alone, was sufficient to reduce the growth rate of
tumor cells but not sufficient to induce enough tumor-cell
death to eliminate the tumor. The addition of a cancer
vaccine further reduced the function of negative immune
regulatory cells and improved the function of antigen-
specific effector cells, leading to tumor eradication
(Figures 3B,C,D and 6E). A lower dose of cabozantinib
(3 mg/kg bw/day) did not synergize with MVA/rF-CEA/
TRICOM to induce tumor regression (data not shown),
suggesting that a minimum serum concentration of cabo-
zantinib is required to achieve synergistic results. Also, if
cabozantinib was discontinued after 10 days, tumor re-
gression was not observed (data not shown), suggesting
that cabozantinib levels must be maintained during vac-
cine treatment to achieve synergistic results.
Remarkably, despite its significant antitumor activity,
cabozantinib treatment induced an increase in Treg in-
filtration into the tumor microenvironment, an increase
that was maintained, though to a lesser degree, when
cabozantinib was combined with vaccine (Figure 5A).
The functional capacity of tumor infiltrating Tregs was
not assayed, however, we were able to demonstrate that
cabozantinib treatment significantly reduced the ability
of peripheral Tregs to perform their regulatory function
(Figure 3B). MVA/rF-CEA/TRICOM treatment alone
similarly reduced the suppressive activity of Tregs. To
our knowledge this is the first time a cancer vaccine,
when used alone, has been shown to interfere with the
negative regulatory capacity of these cells. The combin-
ation of cabozantinib and MVA/rF-CEA/TRICOM, how-
ever, reduced the regulatory capacity of peripheral Tregs
in this mouse model to such an extent that they had
no effect on the proliferation of naïve CD4+ T cells
(Figure 3B). This suggests that while the number of
Tregs in the tumor microenvironment may increase with
this therapeutic regimen, their regulatory capacity may
be impaired.
In these studies, we demonstrated that cabozantinib
treatment could not only modulate the immune landscape
both peripherally and intratumorally, but we also deter-
mined that cabozantinib could induce phenotypic changes
in MC38-CEA tumor cells that increased their sensitivity
to T cell-mediated lysis, hallmarks of immunogenic modu-
lation. Specifically, cabozantinib treatment upregulated
Figure 6 The combination of cabozantinib and immunotherapy significantly reduced tumor growth in a T cell-dependent manner.
(A) Schema of combination therapy study (n =10/group). Tumor growth in mice treated with (B) control, (C) vaccine, (D) cabozantinib, and
(E) combination therapy, including the number of tumor-free mice at day 35. (F) To determine the role of T cells in the efficacy of combination
therapy, we measured tumor growth in control mice with no depletion (open circles), mice receiving combination therapy with no depletion
(closed circles), and mice receiving combination therapy in the absence of CD4+ T cells (open squares) or CD8+ T cells (open triangles) (n =8).
Depletion antibodies were administered on days 1–3, 10, 17, 24, and 31 (arrows). Tumor dimensions were measured weekly. Error bars indicate
mean ± SEM. Statistical analyses were done by Student’s t test. * = P <0.0001 relative to control.
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calreticulin on tumor cells (Figure 1B). We have previously
shown that radiation and chemotherapy can increase
the sensitivity of tumor cells to T cell-mediated lysis through
upregulation of these same molecules [31-33,37]. In-
deed, cabozantinib treatment increased the sensitivity of
MC38-CEA cells to lysis mediated by T cells specific for
either CEA or gp70 (Figure 1C and D). The observation
that cabozantinib treatment did not make MC38-CEA
cells more sensitive to the cytotoxic effects of radiation
(Additional file 1) suggests that cabozantinib’s alteration
of the tumor cells is likely purely immunogenic. To our
knowledge, this is the first time that a small molecule
inhibitor has been shown to induce immunogenic
modulation, and the first time that a single agent hasbeen shown to induce both immunogenic modulation
and immune subset conditioning.
Conclusions
Combination therapy for the treatment of cancer is be-
coming more common as studies continue to demon-
strate the complexity of cancer progression and the
ability of cancer cells to become resistant to single-agent
therapy, particularly that of small molecule inhibitors.
Optimally, combined therapies should synergize to pro-
duce greater anticancer efficacy than that achieved by
either therapy alone. The data presented here demon-
strate that, in addition to its inherent antitumor properties,
cabozantinib is capable of both immunogenic modulation
and immune subset conditioning, two qualities displayed
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Collectively, these data support the clinical investigation of
combination therapy with cabozantinib and cancer vaccines
for the treatment of solid tumors.Methods and materials
Animals
Eight- to 12-week-old female C57/BL6 mice were obtained
from the National Cancer Institute’s Frederick Cancer
Research Facility, Frederick, MD. CEA-transgenic (CEA-Tg)
mice homozygous for the expression of human CEA were
generously provided by Dr. John Shively (Beckman Research
Institute, City of Hope National Medical Center, Duarte,
CA) and were bred and maintained at the National
Institutes of Health (Bethesda, MD) [50].Tumor cells
Murine colon carcinoma MC38 cells expressing human
CEA (MC38-CEA) were generated by retroviral transduc-
tion of MC38 cells with CEA cDNA, as previously de-
scribed [51]. MC38-CEA cells were cultured in complete
medium (DMEM supplemented with 10% fetal bovine
serum, 2 mM glutamine, 1 mM HEPES buffer, 50 μg/mL
gentamicin, 100 IU/mL penicillin, 100 μg/mL strepto-
mycin, and 300 μg/mL G418) at 37°C/5% CO2.Drug preparation
For in vitro studies, cabozantinib malate salt (Exelixis
Inc., South San Francisco, CA) was dissolved in DMSO
(vehicle) at 1.0 mg/mL and stored at −20°C. A dose of
2.5 μg/mL was used for all in vitro experiments. For
in vivo studies, cabozantinib was admixed into standard
rodent diet (Research Diets, New Brunswick, NJ) at a
concentration of 66.7 mg/kg of diet in order to deliver
10 mg/kg bw/day to the animals. To determine the
steady-state serum level of cabozantinib achieved by de-
livering the drug via rodent diet, CEA-Tg C57BL/6 mice
(n =5) were fed control diet or cabozantinib-containing
diet for 10 days. Peripheral blood, acquired by retro-orbital
bleeding, was analyzed for cabozantinib concentration
by LC-MS.Poxviral vaccine constructs
Modified vaccinia Ankara (MVA) and recombinant fowl-
pox (rF) viruses containing transgenes for the murine
costimulatory molecules B7-1, ICAM-1, and LFA-3 (des-
ignated TRICOM) in combination with the human CEA
transgene (MVA/rF-CEA/TRICOM) have been previ-
ously described [52]. For in vivo studies, a priming dose
of MVA-CEA/TRICOM was administered s.c., with
weekly boosts of rF-CEA/TRICOM, both at 1 × 108
plaque-forming units/mouse/dose.Western blotting
MET and VEGFR2 expression was determined by west-
ern blot using rabbit polyclonal antibodies to MET and
VEGFR2 (Abcam, Cambridge, MA). MC38-CEA cells
were lysed using Cell Lysis Buffer containing 1 mM
PMSF (Cell Signalling, Danvers, MA) and 10 μL/mL
HALT Protease/Phosphatase Inhibitor Cocktail (Thermo
Scientific, Rockford, IL) according to the manufacturer’s
protocol, blots were imaged using the Odyssey Infrared
Imaging System (LI-COR Biosciences, Lincoln, NE).
In vitro proliferation analysis
To investigate the effect of cabozantinib on MC38-CEA
cell proliferation, cells were plated in 24-well plates and
treated with cabozantinib or vehicle (DMSO) in vitro for
1, 3, or 5 days, then harvested and counted using trypan
blue counterstaining. To examine the effects of radiation
on cabozantinib-treated MC38-CEA cells, cells were
treated with cabozantinib for 24 h, then irradiated (0 or
5 Gy) by exposure to a Cs-137 source using a
Gammacell-1000 (AECL/Nordion, Kanata, Ontario,
Canada), and then replated. Cells were again harvested
at 24, 48, and 72 h post-irradiation, counted, and assayed
for viability using trypan blue.
In vitro phenotypic analysis
To analyze the effect of cabozantinib on in vitro expres-
sion of immune-relevant proteins, MC38-CEA cells were
treated with cabozantinib or vehicle for 24 h, then stained
with the following antibodies: CD66e/CEA-FITC (AbD
Serotec, Raleigh, NC), H-2Kb-APC (eBioscience, San
Diego, CA), H-2Db-PE, CD54/ICAM-I-PE, CD95/Fas-
FITC (BD Biosciences, San Jose, CA) and calreticulin-APC
(R&D Systems, Minneapolis, MN). 7AAD (BD Biosci-
ences) staining was used to determine cell viability. Cells
were incubated with the antibodies for 30 min at 4°C,
acquired on an LSR II flow cytometer (Becton Dickinson,
Franklin Lakes, NJ), and analyzed using FlowJo software
(TreeStar, Inc., Ashland, OR).
Cytotoxic T lymphocyte killing assay
To evaluate cabozantinib’s ability to alter the sensitivity of
MC38-CEA cells to lysis by CTLs, cells were treated with
cabozantinib, vehicle or left untreated for 24 h, after which
they were harvested and used as targets in a standard CTL
assay. Cells were labeled with 111In-labeled oxyquinoline
(Medi-Physics Inc., Arlington Heights, IL) and coincu-
bated in 96-well round-bottom plates at 37°C/5% CO2
with T572- or gp70-specific effector cells in the absence of
cabozantinib at an effector:target ratio of 30:1. The
H-2Db-restricted CEA-specific CD8+ CTL line, T572, rec-
ognizes the peptide epitope CEA572–579, as previously de-
scribed [53]. The H-2Kb-restricted gp70-specific CD8+
CTL line, gp70, recognizes the peptide epitope p15e604–611
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previously described [54]. After 18 h, supernatants were
harvested and analyzed for the presence of 111In using a
WIZARD2 Automatic Gamma Counter (PerkinElmer,Waltham,
MA). The percentage of tumor lysis was calculated as fol-
lows: % tumor lysis = [(experimental cpm – spontaneous
cpm)/(maximum cpm – spontaneous cpm)] × 100.
In vivo studies
Analysis of immune cell populations
To analyze immune cell populations in the presence or ab-
sence of cabozantinib, CEA-Tg C57BL/6 mice (n =5/group)
were fed control or cabozantinib-containing diet for 10 or
35 days. Spleens were harvested and adjusted to a single-
cell suspension. Red blood cells were removed using ACK
Lysing Buffer (Quality Biologicals Inc., Gaithersburg, MD).
Remaining splenocytes were blocked with mouse Fc
Block (BD Biosciences) for 30 min at 4°C, then stained
with the following antibodies: CD3e-V500, CD4-AF700,
CD8a-Pacific Blue, CD25-FITC, CD11b-V500, Gr-1-
AF700, CD49b-FITC, CD19-PE-Cy7, CD11c-PerCP-
Cy5.5 (BD Biosciences) and MHC II-APC (eBioscience) for
60 min at 4°C. For intracellular staining of cells with FoxP3-
PE, cells were incubated with Fixation/Permeabilization
solution for 16 h at 4°C, then incubated with the anti-
body in Permeabilization Buffer (eBioscience) for 60 min
at room temperature. All samples were acquired on
an LSR II flow cytometer and analyzed using FlowJo
software.
Immune cell function assays
To assess the effect of cabozantinib and MVA/rF-CEA/
TRICOM on immune cell function, CEA-Tg C57BL/6
mice were divided into 4 groups (n =5/group): (a) control,
(b) cabozantinib alone, (c) MVA/rF-CEA/TRICOM alone,
and (d) cabozantinib +MVA/rF-CEA/TRICOM. Mice re-
ceiving cabozantinib were fed cabozantinib-containing
diet on days 0–35. Mice receiving MVA/rF-CEA/TRI-
COM received a priming vaccination with MVA-CEA/
TRICOM on day 0, then booster vaccinations with rF-
CEA/TRICOM on days 7 and 14. Spleens were harvested
on day 35. To examine the function of Tregs, splenocytes
were purified by Histopaque gradient (Sigma-Aldrich, St.
Louis, MO), then CD4+CD25+ Tregs were purified using a
Regulatory T Cell Isolation Kit (Miltenyi Biotec, Auburn,
CA) according to the manufacturer’s instructions. Purified
Tregs were plated with antigen presenting cells (APCs),
irradiated (30 Gy) splenocytes from naïve C57BL/6 mice,
CD4+ T cells, purified from naïve C57BL/6 mice using
a CD4+ T Cell Isolation Kit (Miltenyi Biotec), and anti-
CD3 cross-linking antibody (BD Biosciences) for 72 h.
[3H]-thymidine was added to the culture for the last 12 h
of incubation. Control wells containing Tregs, APCs, and
anti-CD3 without CD4+ cells were used to determine thebackground level of Treg proliferation. Control wells con-
taining CD4+ cells and Concanavalin A (Sigma-Aldrich)
were used to determine the maximum level of CD4+ cell
proliferation. Cells were harvested using a Tomtec cell
harvester (Wallac Inc., Gaithersburg, MD) and [3H]-thy-
midine incorporation was measured using a Wallac 1205
Betaplate MicroBeta Counter (Wallac Inc.) To examine
cytokine production by effector T cells, splenocytes were
incubated with CEA572–579 peptide (GIQNSVSA) (CPC
Scientific, Sunnyvale, CA) for 7 days then purified on a
Histopaque gradient. Effector cells were plated with APCs
in the presence of CEA572 peptide for 24 h. Supernatants
were collected and analyzed for the presence of cytokines
using a mouse Th1/Th2 Cytometric Bead Array (BD Bio-
sciences). Data were acquired using a FACScan flow cyt-
ometer and analyzed using BD CBA analysis software
(Becton Dickinson).
Characterization of the tumor microenvironment
To investigate the effect of cabozantinib and MVA/rF-
CEA/TRICOM on tumor vascularity and immune cell in-
filtration, CEA-Tg C57BL/6 mice were implanted with 3 ×
105 MC38-CEA cells s.c. in the right flank. Fourteen days
post tumor implantation, when tumors were established
(~300 mm3), mice were divided into 4 groups (n =2/
group): (a) control, (b) cabozantinib alone, (c) MVA/rF-
CEA/TRICOM alone, and (d) cabozantinib +MVA/rF-
CEA/TRICOM. Mice treated with cabozantinib were fed
cabozantinib-containing diet on days 14–28. Mice treated
with MVA/rF-CEA/TRICOM received a priming vaccin-
ation with MVA-CEA/TRICOM on day 14 and a booster
vaccination with rF-CEA/TRICOM on day 21. On day 28,
tumors were harvested with a portion of each tumor being
fixed with Z-Fix (Anatech Ltd., Battle Creek, MI), frozen
in OTC (Electon Microscopy Sciences, Hatfield, PA), or
dissociated according to the protocol for preparation of
single-cell suspensions from implanted mouse tumors
(Miltenyi Biotec). Fixed tumor sections were stained with
antibodies to von Willebrand factor at 1:1200 and CD3 at
1:1000 (Dako, Carpinteria, CA). Frozen tumor sections
were stained with rat monoclonal antibodies to CD4 and
CD8 at 1:1500 and 1:700, respectively (Novus Biologicals,
Littleton, CO). Control sections were stained with matched
isotype antibodies. Entire tumor sections were digitally
scanned by an Aperio ScanScope CS scanning system and
analyzed by Aperio ImageScope Viewer software (Aperio
Technologies Inc., Vista, CA) excluding necrotic regions.
Positive tumor regions were determined using the Micro-
vessel Analysis v1 and Positive Pixel Count v9 algorithms,
respectively and are depicted as number of vessels or cells/
tumor. Dissociated tumor was stained for flow cytometric
analysis using the same antibodies and protocol as the
splenic immune cell population analysis with the inclusion
of CD45-BV605 (ebioscience).
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To examine the antitumor effects of cabozantinib and
MVA/rF-CEA/TRICOM, CEA-Tg C57BL/6 mice were
implanted with 3 x 105 MC38-CEA cells s.c. in the right
flank on day 0. On day 4, when tumors became palpable,
mice were divided into 4 groups (n =10/group): (a) con-
trol, (b) cabozantinib alone, (c) MVA/rF-CEA/TRICOM
alone, and (d) cabozantinib +MVA/rF-CEA/TRICOM.
Mice treated with cabozantinib were fed cabozantinib-
containing diet on days 4–35. Mice treated with MVA/
rF-CEA/TRICOM received a priming vaccination with
MVA-CEA/TRICOM on day 4, then weekly booster vac-
cinations with rF-CEA/TRICOM. Tumor dimensions
were measured twice weekly and tumor volumes were
calculated as follows: (length × width2)/2. For depletion
studies, MC38-CEA-bearing CEA-Tg C57BL/6 mice (n =8/
goup) were given either anti-CD4 (GK 1.5) or anti-CD8
(Lyt 2.2) hybridomas i.p. on days 1–3, then at weekly in-
tervals, or left untreated. Depletion was confirmed by flow
cytometric analysis of peripheral blood. All mice, except
for those in the control group, received cabozantinib-
containing diet on days 4–33, a priming vaccination with
MVA-CEA/TRICOM on day 4, then weekly booster vacci-
nations with rF-CEA/TRICOM.
Statistical analysis
GraphPad Prism 5 statistical software (GraphPad Soft-
ware, La Jolla, CA) was used to measure 2-tailed un-
paired Student’s t tests for differences between groups,
with a 95% confidence interval. All data represent the
mean ± SEM for the indicated number of replicates or
individual mice. FlowJo software was used to determine
significant differences in the distribution of flow cytometry
data using the Kolmogorov-Smirnov test.
Additional file
Additional file 1: Cabozantinib treatment does not increase the
sensitivity of MC38-CEA cells to external-beam radiation.
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